ResMed Boosts Q1 FY25 Revenue with Strong Demand for Sleep Devices

Oct 25, 2024

ResMed Inc. (ASX: RMD) surged 7.1% after reporting a robust revenue increase in the first quarter of fiscal 2025, driven by rising demand for its sleep apnea devices and masks. The company's products, which cater to sleep and respiratory health, saw significant growth as global awareness of sleep-related issues continues to expand. This demand helped push ResMed's performance higher, reflecting both its product innovation and the increasing need for effective sleep treatment solutions.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com